share_log

Citigroup Initiates Coverage On Prime Medicine With Neutral Rating, Announces Price Target of $10

Benzinga ·  Dec 8, 2023 07:38

Citigroup analyst Samantha Semenkow initiates coverage on Prime Medicine (NASDAQ:PRME) with a Neutral rating and announces Price Target of $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment